MedElevator
Войти в исследования Clinical endocrinology · 2007
Treatment of hereditary angioneurotic oedema (HANE) with tibolone.
Контролируемое клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ott H W, Mattle V, Hadziomerovic D, Licht P, Döinghaus K, Rubbert A, Manger K, Manger B, Kalden J, Wildt L
Аннотация
OBJECTIVE: Eight women, aged 25-58 years, with hereditary angioneurotic oedema (HANE) were treated with tibolone, a synthetic steroid exhibiting oestrogenic, androgenic and progestational activity.
DESIGN: Pilot study.
RESULTS: Tibolone at a dose of 2.5-7.5 mg/day significantly reduced the number and severity of attacks and the number of ampoules of C1-esterase inhibitor (C1-INH) needed for symptomatic therapy. The efficacy of tibolone was comparable to that of danazol, while the androgenic side-effects were considerably reduced.
CONCLUSIONS: Tibolone may represent an alternative to danazol administration for the prophylaxis of HANE in women.
DESIGN: Pilot study.
RESULTS: Tibolone at a dose of 2.5-7.5 mg/day significantly reduced the number and severity of attacks and the number of ampoules of C1-esterase inhibitor (C1-INH) needed for symptomatic therapy. The efficacy of tibolone was comparable to that of danazol, while the androgenic side-effects were considerably reduced.
CONCLUSIONS: Tibolone may represent an alternative to danazol administration for the prophylaxis of HANE in women.